Relationship between Body Mass Index and Prostate Specific Antigen among Community Men in Port Harcourt, Nigeria
DOI:
https://doi.org/10.47941/ijhs.2372Keywords:
BMI, Obesity, Prostate-cancer, PSA.Abstract
Background: The prevalence of prostate cancer is increasing at a high rate in the Niger Delta region of Nigeria. The role of androgens, age and genetics are established worldwide. Among others, obesity, a consequence of Improvement in quality of life in the oil rich region, which has also been implicated in several conditions like diabetes, hypertension, depression, osteoarthritis and several other malignancies, could be a risk factor. Our aim in this study is to establish a relationship between BMI, an index of obesity and Prostate Specific Antigen (PSA), a marker for prostate cancer.
Materials and Methods: We carried out a community-based observational study in Port Harcourt, Rivers State. The demographic, anthropometric and medical history of men, forty years and above who have lived in the Niger Delta area of Nigeria for over 15 years and who had no prior history of prostate cancer was taken. The BMI and the quantitative PSA of the participants were determined. The corelation of BMI and PSA was established.
Results: A total of 583 respondents participated in the study. Mean age was 60.53 ±7.82. Mean BMI was 24.49 ±3.75. 18% of respondents were underweight, 53.3% were of normal weight, 35.3% were overweight and 7% were obese. The mean PSA was 4.12ng/ml, 84.5% had normal PSA, 15.5% had PSA greater than 4. There was a weak negative correlation between BMI and serum PSA with Pearson correlation of -0.010.
Conclusion: This study shows a negative correlation between BMI and prostate cancer. In view of this inverse relationship between PSA and BMI it may be necessary to reduce the threshold for further evaluations like prostate biopsies in patients with high BMI. Additionally more specific diagnostic tools like ultrasound guidance during prostate biopsy may be helpful.
Downloads
References
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894: i-xii, 1-253
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88.
Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev 2011;12: 438-53.
Prostate biopsy and its outcome in a tertiary hospital in southern Nigeria Danagogo O Ugwa O, Abhulimen V. World Journal of Advanced Research and Reviews 2022;16:343–349
Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2004.159:390–397.
Danagogo O Abhulimen, V, Danagogo T. Lidocaine Gel for Transrectal Prostate Biopsy. International Journal of Innovative Research in Medical Science 2023; 8:25-27.
Obiorah C, Ofuru V. A Population based Study of Prostate Cancer in Rivers State, Nigeria. International journal of biomedical science 2019 ;15 ;55-62.
Van Poppel, Hendrik, Tit Albreht, Partha Basu, Renée Hogenhout, Sarah Collen, and Monique Roobol. "Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future." Nature Reviews Urology 19, no. 9 (2022): 562-572.
Pathirana T, Hayen A, Doust J, et al. Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach. BMJ Open 2019;9:
Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-specific antigen–based screening for prostate cancer. JAMA 2018;319:1914
Hatakeyama S, Yoneyama T, Tobisawa Y, et al. Recent progress and perspectives on prostate cancer biomarkers. Int J Clin Oncol 2017;22:214–21.
Mejak SL, Bayliss J, Hanks SD. Long distance bicycle riding causes prostatespecific antigen to increase in men aged 50 years and over. PLoS One 2013;8:
Wright JL, Lin DW, Stanford JL. The effect of demographic and clinical factors on the relationship between BMI and PSA levels. The Prostate. 2011 Nov;71(15):1631-7.
Oh JJ, Jeong SJ, Lee BK, Jeong CW, Byun SS, Hong SK, Lee SE. Does obesity affect the accuracy of prostate‐specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy. BJU international. 2013 Aug;112(4):E265-71
Kobayashi, M., Mizuno, T., Yuki, H., Kambara, T., Betsunoh, H., Nukui, A., Abe, H., Fukabori, Y., Yashi, M. and Kamai, T. Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold. International journal of clinical oncology 2020;25;472-478.
Fowke JH, Matthews CE. PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Prostate. 2010;70(2):120–5
Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008;71(5):787–91
Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL Jr, Freedland SJ. Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev. 2014; 23: 2936- 2942
Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer–a dose-response meta-analysis of prospective studies. Ann Oncol. 2012; 23: 1665- 1671
Harrison S, Tilling K, Turner EL, Lane JA, Simpkin A, Davis M et al Investigating the prostate specific antigen, body mass index and age relationship: is an age—BMI-adjusted PSA model clinically useful? Cancer Causes Control 2016 27(12):1465–1474
Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomark Prev 2007: 16(1):63–69
Tarantino G, Crocetto F, Vito CD, Martino R, Pandolfo SD, Creta M, Aveta A, Buonerba C, Imbimbo C. Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: A retrospective study. Future science OA. 2020 ;7(3):FSO643.
Hurwitz LM, Yeboah ED, Biritwum RB, Tettey Y, Adjei AA, Mensah JE, Tay E, Okyne V, Truelove A, Kelly SP, Zhou CK. Overall and abdominal obesity and prostate cancer risk in a West African population: An analysis of the Ghana Prostate Study. International journal of cancer. 2020 Nov 15;147(10):2669-76.
Eboreime, O.O. and Atoe, K., 2020. Pattern of age-adjusted serum prostate specific antigen reference intervals among men in Benin City, Nigeria. Journal of Applied Sciences and Environmental Management, 24(1), pp.147-151.
Dada A.O., Soriyan O.O., Okpara H., & Onyenekwu C.P. Egbuagha E. Relationship between prostate-specific antigen and body mass index among men in Lagos, South West Nigeria. Annal of Tropical Pathology 2018, 9, 42 – 6
Parker L.E., Hart K.W., Blonigen B.J., Lindsell C.J., & Barret W.L. Relationship between prostate-specific antigen, age and body mass index in a prostate cancer screening population. American Journal of Clinical Oncology 2012, 35, 470 – 2.
Kubota Y., Seike K., Maeda S., Shinohara Y., Iwata M., & Sugimoto N. Relationship between prostate-specific antigen and obesity in prostate cancer screening: analysis of a large cohort in Japan. International Journal of Urology 2011, 18, 72 – 5.
Fowke J.H., & Matthews C.E.. PSA and body composition by dual X-ray absorptiometry (DXA) in Nhanes. Prostate 2010, 70, 120 – 5.
Meunier, M.E., Neuzillet, Y., Dreyfus, JF. et al. PSA and obesity among men with localized prostate cancer: results of the androcan study. World J Urol 39, 2945–2951 (2021)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Vitalis Obisike Ofuru, Danagogo Okigbeye, Iyama Anslem Chester
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
